Last reviewed · How we verify
NCT04402333: MIRRORS
Minimally Invasive Robotic Surgery, Role in Optimal Debulking Ovarian Cancer, Recovery & Survival
trial testing Robotic Interval Debulking Surgery in Ovarian Cancer in 40 participants. Status unknown.
3 October 2021
Quick facts
| Lead sponsor | Royal Surrey County Hospital NHS Foundation Trust |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 40 |
| Start date | 26 June 2020 |
| Primary completion | 3 October 2021 |
| Estimated completion | 3 October 2021 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Robotic Interval Debulking Surgery
Conditions studied
- Ovarian Cancer — all drugs for Ovarian Cancer →
- Ovarian Neoplasm — all drugs for Ovarian Neoplasm →
- Ovarian Neoplasm Epithelial — all drugs for Ovarian Neoplasm Epithelial →
- Fallopian Tube Cancer — all drugs for Fallopian Tube Cancer →
Sponsor
Royal Surrey County Hospital NHS Foundation Trust
Who can join
18 and older, female only, with Ovarian Cancer or Ovarian Neoplasm. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
MIRRORS "Minimally Invasive Robotic Surgery, Role in Optimal Debulking Ovarian Cancer, Recovery \& Survival" is a new United Kingdom based prospective feasibility study the purpose of which is to establish the feasibility of launching a British multicentre randomised control trial of Robotic interval debulking surgery for ovarian cancer (including cancer of the fallopian tube \& peritoneum) in the future. This initial feasibility study will focus on the ability to recruit patients, acceptability, quality of life, the rate at which it is possible to remove all visible tumour and the rate of conversion to open surgery. Ultimately the investigators would like to determine whether, in selected patients, robotic surgery offers improved quality of life and recovery with equivalent overall and progression free survival. Robotic surgery is unlikely to be suitable in all cases of ovarian cancer, particularly those with large pelvic masses or extensive disease around the upper part of the abdomen, however, it has the potential to provide significant recovery and quality of life benefits to a selected group of patients. MIRRORS - ICG "Peritoneal angiography / perfusion assessment using Indocyanine green (ICG) in patients with advanced ovarian cancers" is a ancillary study within MIRRORS. Using ICG dye, the investigators aim to observe whether there are any changes in the blood vessel pattern associated with the tumour deposits the investigators remove that makes them distinctive. The ICG will not be used to guide where biopsies are taken or tissue is removed. Participation in this ancillary research is not required for participation in the trial.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
MIRRORS ICG: Perfusion Assessment Using Indocyanine Green (ICG) Peritoneal Angiography during Robotic Interval Cytoreductive Surgery for Advanced Ovarian Cancer.
Uwins C, Michael A, Skene SS, Patel H, et al · · 2024 · cited 3× · PMID 39123417 · DOI 10.3390/cancers16152689 -
Minimally invasive surgery in gynecologic oncology: a narrative review of controversies and clinical implications.
Ayoub NL, Shin R, Tseng J, Francoeur AA. · · 2025 · PMID 42211936 · DOI 10.21037/gpm-25-19
Verify or expand the search:
- PubMed search for NCT04402333
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Ovarian Cancer
Currently open trials in the same condition.
- NCT06412120 — Study Evaluating Safety, Tolerability, and Metabolism of Niraparib · Phase 4 · recruiting
- NCT06930755 — Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer · Phase 1 · recruiting
- NCT07318558 — A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) · Phase 3 · recruiting
- NCT07491081 — EARLY Study: Evaluating the Specificity and Feasibility of the EARLY Biomarker Panel for Ovarian Cancer Detection · NA · recruiting
- NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
Other Royal Surrey County Hospital NHS Foundation Trust trials
Trials by the same sponsor.
- NCT07210502 — Side Effects of Low Dose Rate Brachytherapy and Ultra-hypofractionated Radiotherapy in Low to Intermediate Risk Prostate · NA · not yet recruiting
- NCT06638593 — MIRRORS-FROZEN - Comparing Open Vs Robotic Surgery in the Management of Women with Complex Pelvic Adnexal Masses ≤ 8cm. · NA · recruiting
- NCT07046507 — The Exploratory Handheld Optical Coherence Tomography Study in Wilson's Disease · NA · completed
- NCT06613256 — Characterisation of Endothelial Cells in Different Inflammatory Pathologies · recruiting
- NCT06210724 — FIT in Diverticulitis · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04402333 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Royal Surrey County Hospital NHS Foundation Trust
- Last refreshed: 2 September 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04402333.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing